Clinical Trials and Preclinical Infrastructure Asset Map - Genome BC
Clinical Trials and Preclinical Infrastructure Asset Map - Genome BC
Clinical Trials and Preclinical Infrastructure Asset Map - Genome BC
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
CLINICAL TRIALS AND PRECLINICAL INFRASTRUCTURE ASSET MAP<br />
For Quality Control/Assurance, SOPs are in place for consent <strong>and</strong> phlebotomy <strong>and</strong> are being developed<br />
for other research related processes. A checklist is completed for all contracts ensuring protocols<br />
<strong>and</strong> consents have been approved by the REB. All subject personal information is maintained<br />
on password protected computers which are in locked offices or the information in maintained in<br />
a locked office. Access to the information is limited to authorized personnel. As well as attending<br />
research training sessions offered by the British Columbia Health Authorities, all staff complete the<br />
Tri-Council Policy Statement (TCPS) training for the Ethical Conduct for Research Involving Humans<br />
<strong>and</strong> each staff member is regularly observed during the consent process.<br />
Contact:<br />
Feschuk, Connie. Manager. Tel: 604-875-5886. connie.feschuk@vch.ca.<br />
Vancouver Isl<strong>and</strong> Health Authority<br />
VIHA Research Department<br />
The VIHA Research Department supports in-patient <strong>and</strong> out-patient industry-sponsored <strong>and</strong> investigator-driven<br />
trials within the 18 hospitals managed by Vancouver Isl<strong>and</strong> Health Authority (VIHA)<br />
(www.viha.ca/rnd/). These hospitals include Royal Jubilee, Victoria General, <strong>and</strong> Nanaimo Regional<br />
General Hospitals. The Department offers the following services:<br />
• Administration <strong>and</strong> Trial coordination<br />
• Financial Management<br />
• <strong>Clinical</strong> Trial Agreement review<br />
• Liaison with Industry<br />
• Research Ethics Submissions <strong>and</strong> ongoing correspondence<br />
• Quality control <strong>and</strong> supervision of all operational techniques <strong>and</strong> research activities in keeping<br />
with international guidelines<br />
• Clinic space available for patient assessments<br />
• Assurance of protocol compliance <strong>and</strong> quality control of data h<strong>and</strong>ling in compliance with<br />
Good <strong>Clinical</strong> Practice (GCP) <strong>and</strong> applicable regulatory requirements<br />
• St<strong>and</strong>ard Operating Procedures.<br />
The Department currently supports 30 investigators in Phases II, III, <strong>and</strong> IV clinical trials. Investigator<br />
details are listed in Appendix 6:<br />
• Backman, Catherine • Jackson, ML • Petrunia, Dennis<br />
• Barclay A • Jones, C • Piper, HG<br />
• Behrens, C • Kibsey, P • Popkin JS<br />
• Burnett, Stephen • Kirk, P • Schimmele, C<br />
• Connolly, M • Lerch, L • Singh, RA<br />
• Daly, D • Miller, D • Tan Dy, C<br />
• Harder, Curtis • Morris, Dorothy • Tang, Bao<br />
• Hayashi, A • Orrom, William • Weinerman, R<br />
• Hrebicek, O • Penn Andrew • Williams, R<br />
• Horgan, K • Person, D • Wood, G<br />
103
Change language